Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...
The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback